About Novasenta
Novasenta is a Healthcare company based in Pittsburgh (United States) founded in 2018 by Greg Delgoffe, Dario Vignali, and Robert L Ferris. Developer of a drug discovery platform for cancer therapies. Novasenta has raised $55 million across 2 funding rounds from investors including UPMC. Its chief executive, as recorded, is Mani Mohindru. Novasenta offers products and services including Immunotherapy Research and Scientific Consulting. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
A proprietary computational platform for single-cell RNA-based analysis of human tumor samples was established in 2018. Operations are centered in Pittsburgh, United States, within the biotechnology sector focused on immuno-oncology. The pipeline encompasses three programs targeting next-generation drug candidates for cancer treatments, leveraging high-quality human samples to advance therapeutic development.
- Headquarters Pittsburgh, United States
- Founders Greg Delgoffe, Dario Vignali, Robert L Ferris
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website novasenta.com
- Social LinkedIn
- Total Equity Funding$55M (USD)
in 2 rounds
- Latest Funding Round$15M (USD), Series A
Dec 2023
- Investors
Products & Services of Novasenta
Novasenta offers a comprehensive portfolio of products and services, including Immunotherapy Research and Scientific Consulting.
Develops cancer treatments by studying disease and immunity interactions.
Provides expertise in cancer-related immunology and disease research.
Funding Insights of Novasenta
Novasenta has successfully raised a total of $55M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $15 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $55M
- Total Rounds 2
- Last Round Series A — $15M
- First Round $40M
(Jul 2022)
- Investors Count 1
All 2 funding rounds of Novasenta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $15M | Series A | – | – | – |
| Jul 2022 | $40M | Series A | – | UPMC | – |
1 investors in total: 1 institutional.
Investors in Novasenta
Novasenta has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include UPMC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multispecialty hospitals are operated as a nationwide chain. | 1986 | upmc.com | United States |
Investor details for Novasenta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Novasenta
21 people are tracked at Novasenta (8 in leadership, 2 in board & advisors, 11 in team).
| Name | Role | Group |
|---|---|---|
Greg Delgoffe | Co-Founder | Leadership |
Dario Vignali | Co-Founder | Leadership |
Robert L Ferris | Co-Founder | Leadership |
Mani Mohindru | CEO | Leadership |
Pallavi Tawde | VP, Antibody Therapeutics | Leadership |
Sreeram Balasubramanian | Associate Director, Computational Sciences | Leadership |
Daniele Crisi-Couchenour | Director, Operations | Leadership |
Jiayi Yu | Executive Director & Head, R&D Operations | Leadership |
Jeanne Cunicelli | Board Member | Board & advisors |
Matthias Kleinz | Board Member | Board & advisors |
Mason Colbert | Research Technician | Team |
Michael Lyman | SVP, Research & Development | Team |
Sunita Shinde | Laboratory Manager | Team |
Xiaoyan Liang | Principal Scientist | Team |
Zachary Lash | Senior Software Engineer | Team |
Ann Tanilli | Executive Assistant | Team |
Krishnadatt Persaud | Senior Advisor, Antibody Therapeutics | Team |
Philip Dickinson | Fellow, Computational Sciences | Team |
Jatin Machhi | Senior Scientist | Team |
Heather Evers | Animal Technician | Team |
1 more people are available in the full profile.
Complete people profiles for Novasenta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Novasenta
3 dated milestones of Novasenta across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Novasenta is founded.
- Funding First funding round of $40.0M.
- Funding Latest funding round, Series A, of $15.0M.
Competitors of Novasenta
Novasenta has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Novasenta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Novasenta
The website of Novasenta (novasenta.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▼ 8.8% vs previous month
Websites whose visitors overlap most with Novasenta. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| plexision.com | 100% | 3.2K | #5,846,553 | View details | |
| ecmtherapeutics.com | 100% | 2.6K | #6,640,901 | View details | |
| starrlifesciences.com | 99% | 2.8K | #5,697,666 | View details | |
| imaginepharma.com | 98% | View details | |||
| bluespherebio.com | 98% | 2.5K | #6,529,430 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Novasenta
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Novasenta (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novasenta
Complete news archive for Novasenta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novasenta
Novasenta was founded in 2018 and raised its 1st funding round 4 years after it was founded.
Novasenta is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Mani Mohindru is the CEO of Novasenta, as recorded in our data.
Novasenta is a funded company, having raised a total of $55M across 2 funding rounds to date. The company's 1st funding round was a Series A of $40M, raised on Jul 2022.
A proprietary computational platform for single-cell RNA-based analysis of human tumor samples was established in 2018. Operations are centered in Pittsburgh, United States, within the biotechnology sector focused on immuno-oncology. The pipeline encompasses three programs targeting next-generation drug candidates for cancer treatments, leveraging high-quality human samples to advance therapeutic development.
Novasenta offers Immunotherapy Research and Scientific Consulting.
Novasenta has 1 investor. Key investors include UPMC.